Abstract
Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?
MeSH terms
-
Animals
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Arthritis, Rheumatoid / genetics*
-
Arthritis, Rheumatoid / immunology
-
Biomarkers / metabolism
-
Endopeptidases
-
Evidence-Based Medicine
-
Fibroblasts / immunology
-
Gelatinases / genetics
-
Humans
-
Hyperplasia / genetics
-
Membrane Proteins / genetics
-
Phenotype
-
Ribosomal Protein S6 Kinases, 90-kDa / antagonists & inhibitors
-
Ribosomal Protein S6 Kinases, 90-kDa / genetics*
-
Ribosomal Protein S6 Kinases, 90-kDa / immunology
-
Serine Endopeptidases / genetics
-
Synovial Fluid / immunology
Substances
-
Antirheumatic Agents
-
Biomarkers
-
Membrane Proteins
-
Ribosomal Protein S6 Kinases, 90-kDa
-
ribosomal protein S6 kinase, 90kDa, polypeptide 3
-
Endopeptidases
-
Serine Endopeptidases
-
fibroblast activation protein alpha
-
Gelatinases